Pfiz­er, BioN­Tech de­ny Ar­bu­tus and Genevant’s Covid vac­cine patent in­fringe­ment claims

Pfiz­er and BioN­Tech re­spond­ed to a patent in­fringe­ment suit filed by Ar­bu­tus Bio­phar­ma and Genevant, deny­ing the ac­cu­sa­tion that their Covid-19 vac­cine in­fringed on patents held by Ar­bu­tus and li­censed to Genevant.

Pfiz­er and BioN­Tech on Mon­day filed their re­sponse in US Dis­trict Court for the Dis­trict of New Jer­sey to the suit filed in April. Ar­bu­tus and Genevant, par­tial­ly owned by Ar­bu­tus and Roivant, claimed the Covid vac­cine vi­o­lates five Ar­bu­tus patents, which cen­ter around com­pos­ing, man­u­fac­tur­ing, de­liv­er­ing and us­ing nu­cle­ic acid-lipid par­ti­cles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER